Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy

Fig. 2

α-Syn immunoreactivity in Parkinson’s disease. Representative images and corresponding quantification of α-Syn immunoreactivity obtained using IGG-1, IGG-2, IGG-3 and NOV in different brain regions. α-Syn-positive inclusions were detected with both NOV and antibodies in each brain region. IGG-1, IGG-2 and IGG-3 detected significantly higher quantity of α-Syn inclusions than NOV in the putamen, insular cortex, and temporal cortex (P < 0.05). There was no difference between the % area of α-Syn detected by IGG-1 or IGG-2 and NOV in the substantia nigra and internal capsule. IGG-3 detected a significantly higher quantity than NOV in the substantia nigra, basal ganglia and cortical GM (P < 0.0001), and a significant increase was also seen compared to IGG-1 and IGG-2 in substantia nigra, and IGG-2 and in the basal ganglia (P < 0.0001). α-Syn detected by IGG-2 was significantly higher than IGG-3 in temporal cortex (P = 0.0001) and IGG-1 in temporal white matter (P < 0.0001). Error bars show mean ± 95% CI. Scale bar = 100 μm

Back to article page